DEFA14A: Enzo Biochem to Go Private in $37 Million All-Cash Acquisition by Battery Ventures

Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by Battery Ventures for $0.70 per share in an all-cash transaction valued at approximately $37 million, following a comprehensive strategic review.

Summary

• Enzo Biochem, Inc. (Enzo) entered into a Merger Agreement on June 23, 2025, to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures, for $0.70 per share in cash.
• The total consideration for the acquisition is approximately $37 million.
• The offer price represents a 75% premium to Enzo's closing price on April 22, 2025, following the announcement of the formation of the special committee of the Company's Board of Directors, and a 32% premium to the closing price on June 23, 2025, the last trading day before Enzo entered into the Merger Agreement.
• The Company's Board of Directors unanimously approved the merger and resolved to recommend that shareholders vote in favor of the adoption of the Merger Agreement and the consummation of the Merger.
• All of the Company's officers and directors, as well as the Company's largest shareholder, have executed support agreements to vote all of their shares in favor of the transaction.
• Upon closing, Enzo will become a wholly-owned subsidiary of Parent and will be privately held, with its shares delisted from OTCQX.
• Outstanding restricted stock units (RSUs) held by Board members or vested RSUs will be converted into cash at the merger consideration, while other unvested RSUs and all stock options will be canceled without consideration.
• Company Warrants will be canceled, terminated, and extinguished in exchange for a cash amount determined by a Warrant Cancellation Agreement executed by each holder.

Sentiment

Score: 8

Explanation: The document announces an all-cash acquisition at a substantial premium, unanimously approved by the Board and supported by major shareholders, providing immediate and certain value to investors. While some equity awards are canceled without consideration, the overall terms are highly favorable for common shareholders.

Positives

• The all-cash transaction provides immediate liquidity and certainty of value to shareholders.
• The acquisition price of $0.70 per share represents a significant premium of 75% to the Company's closing price on April 22, 2025 (following the strategic review announcement) and approximately 32% to the closing price on June 23, 2025.
• The Company's Board of Directors unanimously determined the merger to be in the best interests of the Company and its shareholders and approved the transaction.
• All of the Company's officers and directors, along with its largest shareholder, have executed voting and support agreements, indicating strong internal backing for the merger.

Negatives

• Company restricted stock units (RSUs) that are unvested and not held by Board members, and all outstanding stock options, will be canceled without any consideration payable.
• The Company will become privately held and its shares will no longer be listed on public market exchanges, removing public trading access for investors.
• The Company may be required to pay Parent a termination fee of $2.5 million under certain specified circumstances, such as a change in Board recommendation or if an alternative transaction is consummated within 12 months of termination.
• The Company will be required to reimburse Parent's expenses up to a cap of $1 million under certain termination conditions.

Risks

• The ability of the Company and Acquirer to complete the Merger on the proposed terms or anticipated timeline, or at all, including risks and uncertainties related to securing the necessary approval of the Company's shareholders.
• Compliance with the covenants contained in the Merger Agreement and satisfaction of other closing conditions to consummate the Merger.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the definitive transaction agreement relating to the Merger.
• Risks related to diverting the attention of the Company's management from ongoing business operations.
• Significant transaction costs and/or unknown or inestimable liabilities.
• The risk of shareholder litigation in connection with the Merger, including resulting expense or delay.
• The merger is conditioned upon holders (excluding certain holders) of no more than 10% of the outstanding shares of Company Common Stock exercising statutory dissenters' rights.
• The merger is conditioned upon the holders of all Company Warrants having duly executed and delivered a Warrant Cancellation Agreement that remains in full force and effect.

Future Outlook

The transaction is anticipated to close in the third quarter of the calendar year 2025, subject to the satisfaction of customary closing conditions, including shareholder approval. Following the closing, Enzo Biochem will transition to a privately held company, and its shares will be delisted from public market exchanges.

Management Comments

• Steven Pully, Chairman of the Board and member of the Strategic Committee, stated: 'This transaction is the outcome of a thorough process to evaluate all potential paths to maximize shareholder value.'
• Steven Pully also commented: 'After careful consideration, the Board unanimously determined that the all-cash offer from Battery delivers immediate and compelling value for our shareholders.'

Industry Context

The acquisition of Enzo Biochem by Battery Ventures, a technology-focused investment firm, suggests a strategic move to potentially leverage technology for growth or operational efficiency within the life sciences sector. The transition to private ownership is a common strategy for companies seeking to undergo significant restructuring, invest for long-term growth away from public market scrutiny, or optimize operations without the pressures of quarterly reporting and public market expectations. This aligns with a broader trend of private equity firms investing in specialized sectors like life sciences to unlock value.

Comparison to Industry Standards

• The acquisition premium of 75% to the price on April 22, 2025, and 32% to June 23, 2025, is substantial and generally considered favorable for shareholders in an all-cash transaction, especially for a company traded on OTCQX, which typically has lower liquidity compared to major exchanges.
• The treatment of equity awards, where unvested RSUs and all stock options are canceled without consideration while vested RSUs and warrants receive cash, is a common practice in all-cash mergers, aligning with standard M&A compensation practices.
• The specified termination fees ($2.5 million for the Company, $1 million for Parent) and expense reimbursement caps ($1 million for Parent's expenses) are within typical ranges for transactions of this size and complexity, serving as standard deal protection mechanisms.

Management Changes

Corporate Governance

Legal Proceedings

• The document identifies a risk of shareholder litigation in connection with the Merger, including resulting expense or delay.
• The Company is obligated to keep Parent reasonably informed of the status of any shareholder demand, action, or other proceeding related to the Merger and to cooperate in its defense or settlement, not settling without Parent's prior written consent.

Related Party Transactions

• All of the Company's officers and directors and the Company's largest shareholder have executed voting and support agreements in favor of Parent and Merger Sub, agreeing to vote their shares in favor of the Merger and against any alternative transaction proposal.
• The Company represents that, since January 1, 2022, there have been no transactions, agreements, arrangements, or understandings between the Company or its Subsidiaries and any director or executive officer of the Company or its Affiliates that would be required to be disclosed under Item 404 of Regulation S-K, other than ordinary course employment agreements and similar employee arrangements.

Stakeholder Impact

• **Shareholders**: Common shareholders will receive immediate cash at a significant premium, providing liquidity and certainty of value. However, they will lose future equity upside potential and public trading access as the company becomes private.
• **Employees**: Continuing employees will receive service credit for vesting, eligibility, and benefit levels under new plans. Pre-existing condition exclusions will be waived for health benefits. However, unvested restricted stock units and all stock options will be canceled without consideration, potentially impacting the long-term incentives of some employees.
• **Management**: Board members and vested RSU holders will receive cash consideration. Current officers and directors have signed support agreements to facilitate the merger. Directors will resign at the Effective Time.
• **Warrant Holders**: Holders of Company Warrants will have their warrants canceled in exchange for a cash amount determined by a Black-Scholes valuation, providing a cash payout for their equity instruments.
• **Creditors/Lenders**: The Company is required to provide a payoff letter for all existing indebtedness for borrowed money, ensuring these obligations are repaid in full at closing, which is beneficial for creditors.

Next Steps

• The Company will prepare and use its best efforts to file a preliminary proxy statement with the SEC within five business days (but no later than ten business days) after the date of the Merger Agreement.
• The Company will mail the proxy statement to its shareholders as promptly as reasonably practicable after the resolution of any SEC comments.
• The Company will convene and hold a Special Meeting of Shareholders to obtain the Company Shareholder Approval.
• The Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent.
• The Company will cooperate with Parent to cause the removal of Company Common Stock from trading on OTCQX and its deregistration under the Exchange Act as promptly as practicable after the Effective Time.
• The Company will purchase a six-year prepaid tail policy for directors and officers liability insurance at or prior to the Effective Time.
• The Company will deliver resignations executed by each director of the Company in office immediately prior to the Effective Time, effective at the Effective Time.
• The Company will use reasonable best efforts to terminate specific Leases prior to the Closing.

Key Dates

Recommendation

Keywords

Enzo Biochem, Battery Ventures, Merger, Acquisition, Private Equity, Life Sciences, Biotechnology, OTCQX, Shareholder Value, Strategic Review, Delisting, Cash Transaction, Corporate Governance, SEC Filing, Form 8-K